Bristol-Myers Squibb: News
 
Partnering News
April 16, 2015Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North AmericaApril 8, 2015Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.April 6, 2015Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular DiseasesMarch 4, 2015Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer ImmunotherapyFebruary 23, 2015Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc.February 23, 2015Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related IndicationsJanuary 29, 2015Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo® in Advanced Refractory Solid TumorsJanuary 13, 2015Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid TumorsJanuary 5, 2015Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic DiseasesDecember 10, 2014Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid TumorsNovember 24, 2014Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor TypesNovember 3, 2014Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary FibrosisOctober 30, 2014Bristol-Myers Squibb and Lonza Expand Manufacturing AgreementOctober 28, 2014Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted TherapyOctober 6, 2014Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic MalignanciesAugust 20, 2014Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination RegimenAugust 4, 2014Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U.S. Academic Research InstitutionsJuly 23, 2014Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and TaiwanMay 27, 2014Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology TargetsMay 27, 2014Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel ImmunotherapiesApril 29, 2014Bristol-Myers Squibb Acquires iPierian, Inc.March 17, 2014Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint PathwaysSeptember 3, 2013Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart DiseaseAugust 31, 2013New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were UncommonJuly 29, 2013Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.